Tranexamic acid in patients undergoing coronary-artery surgery

New England Journal of Medicine

Volumn 376, Issue 19, 2017, Pages 1891-1893

  Myles, Paul S ^a   Smith, Julian A ^a   Painter, Thomas ^b  

^a MONASH UNIVERSITY   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL (TOPIC); CORONARY ARTERY SURGERY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; LETTER; LOW DRUG DOSE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; SEIZURE; SINGLE DRUG DOSE; ARTERY; CORONARY ARTERY BYPASS GRAFT; OPERATIVE BLOOD LOSS; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDY;

ANTIFIBRINOLYTIC AGENTS; ARTERIES; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CORONARY ARTERY BYPASS; HUMANS; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; TRANEXAMIC ACID;

EID: 85044536741     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1703369     Document Type: Letter

References (2)

1. Lecker I, Wang DS, Romaschin AD, Peterson M, Mazer CD, Orser BA. Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest 2012; 122: 4654-66.
2. Furtmuller R, Schlag MG, Berger M, et al. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect. J Pharmacol Exp Ther 2002; 301: 168-73.